Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiopoietin-like protein 8 (ANGPTL8), also known as betatrophin, is a secreted glycoprotein that regulates serum triglyceride levels by modulating lipoprotein lipase (LPL) activity. It acts as an inhibitor of LPL and forms complexes with other angiopoietin-like proteins, such as ANGPTL3 and ANGPTL4, to regulate lipid metabolism. While there has been interest in its potential role in promoting pancreatic beta-cell proliferation and insulin release, this remains controversial. Dysregulation of ANGPTL8 has been associated with metabolic disorders such as liver steatosis and potentially type II diabetes. It has also shown potential therapeutic effects in experimental models of Adriamycin-induced cardiomyopathy.
Inhibits lipoprotein lipase (LPL) activity by forming complexes with ANGPTL3 or ANGPTL4, promoting LPL dissociation into inactive monomers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiopoietin-like protein 8 (ANGPTL8).